Pharmaceuticals

This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, INR testing, NOAC, OAC, IV administered drugs such as Heprin, and dual antiplatelet therapy.

Novo Nordisk A/S: Semaglutide 2.4 mg reduces the risk of major adverse cardiovascular events by 20% in adults with overweight or obesity in the SELECT trial

News | Cardiovascular Clinical Studies

Major Adverse Cardiovascular Events Reduced in Overweight/Obese Patients with Wegovy, per SELECT Trial

August 9, 2023 — Novo Nordisk announced the headline results from the SELECT cardiovascular outcomes trial. The double ...

August 09, 2023

LX2020 preclinical studies demonstrated proof-of-concept with treatment restoring desmosomal integrity, reducing arrhythmias, and extending survival in a clinically relevant murine model

News | Pharmaceuticals

LEXEO Therapeutics Announces FDA Clearance of IND for LX2020, an AAV-based Gene Therapy Candidate for PKP2 Arrhythmogenic Cardiomyopathy

August 1, 2023 —LEXEO Therapeutics, a clinical-stage gene therapy company advancing adeno-associated virus (AAV)-based ...

August 01, 2023

Here is a look at what DAIC viewers were reading during the month of July

Feature | Cardiovascular Business | By Melinda Taschetta-Millane

What Viewers Were Reading in July

Here is a look at what DAIC viewers were reading during the month of July:

1. Lessons Learned from World’s First ...

August 01, 2023

New U.S. patent provides intellectual property (IP) protection until December 2040, and may qualify for term extension beyond 2040

News | Hypertension

Tenax Therapeutics Issued U.S. Patent for Oral Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

July 26, 2023 — Tenax Therapeutics, Inc, a specialty pharmaceutical company focused on identifying, developing and ...

July 26, 2023

Eli Lilly and Company and Versanis Bio today announced a definitive agreement for Lilly to acquire Versanis, a private clinical-stage biopharmaceutical company focused on the development of new medicines for the treatment of cardiometabolic diseases

News | Cardiovascular Business

Lilly to Acquire Versanis to Improve Patient Outcomes in Cardiometabolic Diseases

July 14, 2023 — Eli Lilly and Company and Versanis Bio today announced a definitive agreement for Lilly to acquire ...

July 14, 2023

Leqvio can now be used earlier in LDL-C treatment as an adjunct to diet and statin therapy for patients who have not had a cardiovascular event but are at an increased risk of heart

News | Pharmaceuticals

FDA Approves Expanded Indication for Leqvio

July 10, 2023 — Novartis announced that the US Food and Drug Administration (FDA) has approved a label update for Leqvio ...

July 10, 2023

Coronary computed tomography angiography is a cheaper, less-invasive alternative to intravascular ultrasound in pharmaceutical clinical trials

Feature | Cardiac Imaging | By Matthew Jay Budoff, MD, FACC, FAHA

The Benefits of Coronary CTA in Pharmaceutical Clinical Trials

Coronary computed tomography angiography (CCTA) is cheaper, easier to use and its results are easier to understand than ...

July 10, 2023

Approval based on two positive Phase 3 trials, EXPLORER-HCM and VALOR-HCM, demonstrating significant benefit in patients treated with CAMZYOS versus placebo

News | Pharmaceuticals

Bristol Myers Squibb Receives European Commission Approval of CAMZYOS (mavacamten), for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM)

June 28, 2023 — Bristol Myers Squibb announced that the European Commission (EC) has approved CAMZYOS (mavacamten, 2.5 ...

June 28, 2023

LODOCO (colchicine, 0.5 mg tablet) Reduces Cardiac Event Risk in Adult Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) by an Additional 31% on Top of Standard of Care

News | Pharmaceuticals

U.S. FDA Approves First Anti-Inflammatory Drug for Cardiovascular Disease

June 20, 2023 — AGEPHA Pharma USA, LLC, announced that, following a Priority Review, the U.S. Food and Drug ...

June 20, 2023

News | Cardiovascular Clinical Studies

Esperion Presents Results from New Analysis on Cardiovascular Benefits with Bempedoic Acid Treatment at ENDO 2023

June 16, 2023 — Esperion presented results from an analysis comparing the cardiovascular risk reduction benefits of bemp ...

June 16, 2023

INJECTAFER is now the first and only intravenous (IV) iron replacement therapy indicated for adult patients with heart failure who have iron deficiency

News | Heart Failure

Injectafer Approved in the U.S. for the Treatment of Iron Deficiency in Adult Patients with Heart Failure

June 7, 2023 — Daiichi Sankyo, Inc. and American Regent, Inc., a Daiichi Sankyo Group company, announced that the U.S ...

June 07, 2023

INPEFA reduced the risk of total occurrence of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits by 33% compared to placebo in the SOLOIST-WHF study

News | Pharmaceuticals

Lexicon Announces FDA Approval of INPEFA (Sotagliflozin) for Treatment of Heart Failure

June 5, 2023 — Lexicon Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved I ...

June 05, 2023

Analysis of TWILIGHT trial shines light on Effect of Therapies following percutaneous coronary intervention

News | SCAI

Ticogrelor Monotherapy Post PCI Associated with Similar Rates of Revascularization as Duel Antiplatelet Therapy

June 1, 2023 — New insights from the TWILIGHT trial showed that ticagrelor monotherapy after three months of ticagrelor ...

June 01, 2023

There are currently no FDA approved treatments for PH-HFpEF, a condition affecting more than 1,600,000 North Americans, with estimates indicating a prevalence of more than 2,000,000 patients by 2030

News | Pharmaceuticals

Tenax Therapeutics Achieves Major Milestone as USPTO Grants Notice of Allowance for U.S. Patent Application Covering Use of Oral Levosimendan (TNX-103) in PH-HFpEF

May 31, 2023 — Tenax Therapeutics, Inc., a specialty pharmaceutical company focused on identifying, developing and ...

May 31, 2023

This research-use-only offering supports the discovery, development, and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases

News | Pharmaceuticals

Cardio Diagnostics Holdings, Inc Unveils The CardioInnovate360 BioPharma Research System

May 15, 2023 — Cardio Diagnostics Holdings, Inc, a precision cardiovascular medicine company, today announced the ...

May 15, 2023